Development of an Individualized Immune Prognostic Signature for Clear Cell Renal Cell Carcinoma through the Identification of Differential Immune Genes

Figure 3

Construction and validation of an immunity-based risk signature. Distribution of the risk score, survival time, and survival status of the patients with KIRC in the (a) TCGA, (b) TCGA-Train, (c) TCGA-Test, (d) E-MTAB-1980, and (e) E-MTAB-3267 cohorts. Kaplan–Meier survival curves based on the risk model in the (f) TCGA, (g) TCGA-Train, (h) TCGA-Test, (i) E-MTAB-1980, and (j) E-MTAB-3267 cohorts. Receiver operating characteristic curve and the corresponding AUCs of the risk model in the (k) TCGA, (l) TCGA-Train, (m) TCGA-Test, (n) E-MTAB-1980, and (o) E-MTAB-3267 cohorts.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)

(n)

(o)